About this episode

This episode features Sean Werner discussing the advancements and challenges in cell and gene therapy development.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sean Werner, Chief Technology Officer at BioLife Solutions, Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sean, covering: The value of learning your craft in big pharma, and the steep transition from technical expert to President of a spinout Why BioLife moved from board involvement to acquiring Sean’s company outright The critical role of cryopreservation, and why it remains an overlooked risk in cell therapy development His perspective on the cell and gene therapy space, and why there is still plenty of reason for optimism The rise of China’s biotech ecosystem and why its growth is a positive for the global industry Why CGT is set to diverge into more specialised areas, unlocking new therapeutic and patient applications Sean Werner is the Chief Technology Officer at BioLife Solutions, a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. BioLife acquired Sexton Biotechnologies in 2021 where Sean was President of the company known for providing processing…

More episodes of Molecule to Market: Inside the outsourcing space

• Bora Live Panel - The Voice of the Customer · May 8, 2026 · 56 min
• Inside the mind of the CMO outsourcer · April 24, 2026 · 56 min
• The unconventional CEO · April 17, 2026 · 46 min
• DCAT Live - Morgan Stanley CDMO CEO Dinner · April 3, 2026 · 46 min
• DCAT Live Panel - Stick or Twist with Capacity in Times of Uncertainty · March 30, 2026 · 52 min
• From consulting stay at home dad to global CRO CEO · March 20, 2026 · 57 min

Explore listener stats, chart rankings, contacts and more on the Molecule to Market: Inside the outsourcing space podcast page.